# DENND2D

## Overview
DENND2D is a gene that encodes the DENN domain-containing protein 2D, which functions as a guanine nucleotide exchange factor (GEF) for Rab GTPases. These proteins are integral to various cellular processes, including vesicle transport and signal transduction. The DENND2D protein specifically facilitates the activation of Rab proteins by promoting the exchange of GDP for GTP, a critical step in membrane trafficking and intracellular signaling pathways (KANDA2013Downregulation; Hibino2014Reduced). In healthy cells, DENND2D is active in the cytoplasm, where it plays a vital role in retrograde trafficking and maintaining cellular homeostasis (Marat2011DENN). The gene has been implicated in several cancers, where its downregulation is often associated with poor prognosis, highlighting its potential role as a tumor suppressor (KANDA2013Downregulation; Hibino2014Reduced).

## Function
The DENND2D gene encodes a protein that is part of the DENN domain family, which functions as a guanine nucleotide exchange factor (GEF) for Rab GTPases. These GTPases are involved in various cellular processes, including vesicle transport, signal transduction, and cytoskeleton formation (KANDA2013Downregulation; Hibino2014Reduced). The DENND2D protein specifically facilitates the exchange of GDP for GTP, activating Rab proteins, which is crucial for membrane trafficking and intracellular signaling pathways (KANDA2013Downregulation).

In healthy human cells, DENND2D is active in the cytoplasm, where it influences vesicular trafficking pathways by activating specific Rab proteins (Marat2011DENN). This activity is essential for the retrograde trafficking of the mannose phosphate receptor from late endosomes to the trans-Golgi network, a process critical for maintaining cellular homeostasis (Marat2011DENN). The DENND2D protein's role in these processes underscores its importance in normal cellular function and its potential impact on organismal outcomes, such as growth and differentiation (Hibino2014Reduced). Despite its significant role in cellular processes, the specific functions of DENND2D in healthy human cells, particularly in the context of non-cancerous tissues, are not extensively detailed in the available literature (Kanda2014Prognostic).

## Clinical Significance
The DENND2D gene has been implicated in several types of cancer due to its role as a tumor suppressor gene. In esophageal squamous cell carcinoma (ESCC), DENND2D is often downregulated due to promoter hypermethylation, which is associated with poor prognosis and reduced survival rates. This downregulation is considered an independent prognostic factor in ESCC, highlighting its clinical significance in the progression of this cancer type (Hibino2014Reduced).

In hepatocellular carcinoma (HCC), DENND2D downregulation is also linked to promoter hypermethylation, contributing to early recurrence of the disease. The hypermethylation of the DENND2D promoter is a significant molecular alteration in hepatocarcinogenesis, and its downregulation is associated with shorter disease-specific and recurrence-free survival (KANDA2013Downregulation).

In colorectal cancer (CRC), lower expression of DENND2D is associated with increased cell proliferation and migration, as well as poorer prognosis. DENND2D suppresses the MAPK pathway, and its knockdown leads to larger tumor volumes and more metastases in vivo. Patients with stage IV colon cancer lacking DENND2D expression benefit more from neoadjuvant chemotherapy, suggesting its potential as a biomarker for treatment response (Ma2022Stage).

In gastric cancer, DENND2D downregulation due to promoter hypermethylation is linked to poor prognosis, with associations to advanced tumor stage and metastasis (Kanda2014Prognostic).

## Interactions
DENND2D is a protein that primarily functions as a guanine nucleotide exchange factor (GEF) for Rab GTPases, specifically Rab9 and Rab35, which are involved in membrane trafficking processes. The DENN domain of DENND2D is responsible for its GEF activity, facilitating the exchange of GDP for GTP on Rab proteins, thereby activating them (Kanda2014Prognostic; Marat2011DENN). 

In the context of non-small cell lung cancer (NSCLC), DENND2D is directly targeted by miR-522, a microRNA that binds to the 3' untranslated region (3' UTR) of DENND2D, inhibiting its translation and reducing its protein levels. This interaction has been confirmed through luciferase reporter assays, which demonstrate that miR-522 significantly decreases the activity of the wild-type 3' UTR of DENND2D (Zhang2016Downregulation). 

DENND2D is also implicated in the regulation of the Rab signaling pathway, which is crucial for processes such as EGFR trafficking and macrophage activation during sepsis (Ma2024Development). Despite these insights, specific physical interactions of DENND2D with other proteins or nucleic acids beyond its role as a GEF and its regulation by miR-522 are not detailed in the available literature.


## References


[1. (KANDA2013Downregulation) MITSURO KANDA, SHUJI NOMOTO, HISAHARU OYA, HIDEKI TAKAMI, SOKI HIBINO, MITSUHIRO HISHIDA, MASAYA SUENAGA, SUGURU YAMADA, YOSHIKUNI INOKAWA, YOKO NISHIKAWA, MIKAKO ASAI, TSUTOMU FUJII, HIROYUKI SUGIMOTO, and YASUHIRO KODERA. Downregulation of dennd2d by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. International Journal of Oncology, 44(1):44–52, November 2013. URL: http://dx.doi.org/10.3892/ijo.2013.2165, doi:10.3892/ijo.2013.2165. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2013.2165)

[2. (Zhang2016Downregulation) Tianze Zhang, Yingying Hu, Jin Ju, Liangyu Hou, Zhange Li, Dan Xiao, Yongchao Li, Jianyu Yao, Chao Wang, Yong Zhang, and Linyou Zhang. Downregulation of mir-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting denn/madd domain containing 2d. Scientific Reports, January 2016. URL: http://dx.doi.org/10.1038/srep19346, doi:10.1038/srep19346. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep19346)

[3. (Hibino2014Reduced) Soki Hibino, Mitsuro Kanda, Hisaharu Oya, Hideki Takami, Dai Shimizu, Shuji Nomoto, Masahiko Koike, Suguru Yamada, Goro Nakayama, Tsutomu Fujii, Hiroyuki Sugimoto, Michitaka Fujiwara, and Yasuhiro Kodera. Reduced expression of dennd2d through promoter hypermethylation as an adverse prognostic factor in squamous cell carcinoma of the esophagus. Journal of Clinical Oncology, 32(3_suppl):58–58, January 2014. URL: http://dx.doi.org/10.1200/jco.2014.32.3_suppl.58, doi:10.1200/jco.2014.32.3_suppl.58. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1200/jco.2014.32.3_suppl.58)

[4. (Marat2011DENN) Andrea L. Marat, Hatem Dokainish, and Peter S. McPherson. Denn domain proteins: regulators of rab gtpases. Journal of Biological Chemistry, 286(16):13791–13800, April 2011. URL: http://dx.doi.org/10.1074/jbc.R110.217067, doi:10.1074/jbc.r110.217067. This article has 299 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.R110.217067)

[5. (Ma2022Stage) Wen-juan Ma, Yukun Chen, Jian-hong Peng, Chaoming Tang, Ling Zhang, Min Liu, Shanshan Hu, Haineng Xu, Hua Tan, Yangkui Gu, Zhi-zhong Pan, Gong Chen, Zhong-guo Zhou, and Rong-xin Zhang. Stage iv colon cancer patients without dennd2d expression benefit more from neoadjuvant chemotherapy. Cell Death &amp; Disease, May 2022. URL: http://dx.doi.org/10.1038/s41419-022-04885-8, doi:10.1038/s41419-022-04885-8. This article has 3 citations.](https://doi.org/10.1038/s41419-022-04885-8)

[6. (Ma2024Development) Guangxin Ma, Xiaolin Wu, Cui Qi, Xiaoning Yu, and Fengtao Zhang. Development of macrophage-associated genes prognostic signature predicts clinical outcome and immune infiltration for sepsis. Scientific Reports, January 2024. URL: http://dx.doi.org/10.1038/s41598-024-51536-3, doi:10.1038/s41598-024-51536-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-51536-3)

[7. (Kanda2014Prognostic) Mitsuro Kanda, Dai Shimizu, Shuji Nomoto, Hideki Takami, Soki Hibino, Hisaharu Oya, Ryoji Hashimoto, Masaya Suenaga, Yoshikuni Inokawa, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Tsutomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, and Yasuhiro Kodera. Prognostic impact of expression and methylation status of denn/madd domain-containing protein 2d in gastric cancer. Gastric Cancer, 18(2):288–296, April 2014. URL: http://dx.doi.org/10.1007/s10120-014-0372-0, doi:10.1007/s10120-014-0372-0. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10120-014-0372-0)